1. Pink Sheet
  2. >>Vaccines

Coronavirus Notebook: EMA Starts Review Of Sanofi/GSK Vaccine, UK Boosts mRNA Lipid Production

 
• By Ian Schofield

Sanofi/GSK's vaccine is under review in the EU and the UK government has awarded a grant to a company to allow it to increase its production of a key component of mRNA vaccines. Also, EU member states have proposed ways of improving the supply and donation of COVID-19 vaccines, including for those fleeing the conflict in Ukraine. Germany’s InflaRx has reported “encouraging” results with its anti-inflammatory drug vilobelimab in seriously ill patients.

Six vials of coronavirus vaccine. Glass bottles with red and blue caps. Two-stage injection against COVID-19 virus. 3D rendering - Image ID: 2H5DPKG
Vidprevtyn would be the EU's sixth COVID-19 vaccine • Source: Alamy

The European Medicines Agency has begun assessing a conditional marketing authorization application (MAA) filed by Sanofi and GlaxoSmithKline plc for their COVID-19 vaccine, Vidprevtyn.

The vaccine is an adjuvanted recombinant protein-based product that includes an S-protein antigen from Sanofi and an adjuvant platform from GSK

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Vaccines

More from Pink Sheet

FDA Use Of Artificial Intelligence Will Help US Retain Biotech Leadership

 
• By Sue Sutter and Derrick Gingery

At a House subcommittee hearing, HHS Secretary Robert F. Kennedy Jr. rebutted lawmaker concerns that NIH cuts will drive research and scientists to other countries and said he does not want to advise parents on vaccinating children for measles, chickenpox or polio.

HHS Secretary Kennedy Says Trump Will Make Final Decision On Mifepristone Policy

 
• By Derrick Gingery

With an FDA review ongoing, Kennedy’s admission, made during a Senate hearing on the Health and Human Services Department’s budget request, suggests political officials could supersede scientific decisions.

Industry Leaders Grapple With Trump’s Most Favored Nation Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on the impact of Trump’s most favored nation pricing executive order on US and European markets.